Glenmark Of India Plans U.S. Acquisition To Market Specialty Drugs
This article was originally published in PharmAsia News
India's Glenmark Pharmaceuticals plans to acquire a U.S. company in a move to enter the U.S. market for its specialty drugs business. Currently, Glenmark specialty products are marketed in all markets except the United States and Japan. Glenmark CEO Glenn Saldanha would not comment on the size or timing of an acquisition, but confirmed the company does want to market its specialty products in regulated markets, particularly the United States. That product line is expected to be worth $35 million to the firm in the next fiscal period. (Click here for more
You may also be interested in...
PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse
NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.